Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions.

Liang S, Yao J, Bourne PA, diSant'Agnese PA, Huang J, Lei JY.

Am J Clin Pathol. 2004 Nov;122(5):747-51.

PMID:
15491971
2.

Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.

Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY.

Am J Clin Pathol. 2005 Aug;124(2):282-7.

PMID:
16040301
3.

Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions.

Feng W, Zhou Z, Peters JH, Khoury T, Zhai Q, Wei Q, Truong CD, Song SW, Tan D.

Arch Pathol Lab Med. 2011 Aug;135(8):1024-31. doi: 10.5858/2009-0617-OAR2.

PMID:
21809994
4.

An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.

Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z.

Am J Surg Pathol. 2009 Apr;33(4):521-5. doi: 10.1097/PAS.0b013e31818aada9.

PMID:
19047899
5.

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.

Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28.

PMID:
19638963
6.

Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.

Abraham SC, Wang H, Wang KK, Wu TT.

Am J Surg Pathol. 2008 Jul;32(7):1068-74. doi: 10.1097/PAS.0b013e318160c579.

PMID:
18496141
7.

CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

Hansel DE, Dhara S, Huang RC, Ashfaq R, Deasel M, Shimada Y, Bernstein HS, Harmon J, Brock M, Forastiere A, Washington MK, Maitra A, Montgomery E.

Am J Surg Pathol. 2005 Mar;29(3):390-9.

PMID:
15725809
8.

Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus.

Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, Woodward T, Klingler PJ.

Arch Surg. 1997 Jul;132(7):728-33.

PMID:
9230856
9.

Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.

Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2006 Apr;30(4):423-35.

PMID:
16625087
10.

Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.

Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R.

Cancer. 2007 Feb 15;109(4):668-74.

11.

Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.

Hermann B, Li Y, Ray MB, Wo JM, Martin RC 2nd.

Arch Surg. 2005 Dec;140(12):1204-9; discussion 1209.

PMID:
16365243
12.

Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.

Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5. doi: 10.1158/1055-9965.EPI-07-2734.

13.

Expression of PCNA and p53 in esophageal dysplasia and esophageal carcinoma.

Murakami S, Uchida Y, Takeno S, Noguchi T, Matsumoto K, Shimoda H.

Surg Today. 1997;27(7):593-9.

PMID:
9306559
14.

Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia.

Sagatys E, Garrett CR, Boulware D, Kelley S, Malafa M, Cheng JQ, Sebti S, Coppola D.

Hum Pathol. 2007 Oct;38(10):1526-31. Epub 2007 Jul 19.

PMID:
17640711
15.

Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.

Scheil-Bertram S, Lorenz D, Ell C, Sheremet E, Fisseler-Eckhoff A.

Mod Pathol. 2008 Aug;21(8):961-7. doi: 10.1038/modpathol.2008.73. Epub 2008 May 23.

16.

Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.

Sarbia M, Bektas N, Müller W, Heep H, Borchard F, Gabbert HE.

Cancer. 1999 Dec 15;86(12):2597-601.

PMID:
10594854
17.

Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.

Geddert H, Heep HJ, Gabbert HE, Sarbia M.

Cancer. 2002 Jan 1;94(1):212-8.

18.

Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.

Glickman JN, Blount PL, Sanchez CA, Cowan DS, Wongsurawat VJ, Reid BJ, Odze RD.

Hum Pathol. 2006 Oct;37(10):1304-15. Epub 2006 Jul 20.

PMID:
16949933
19.

Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.

Asthana N, Mandich D, Ligato S.

Am J Surg Pathol. 2008 Oct;32(10):1581-5. doi: 10.1097/PAS.0b013e3181753aa6.

PMID:
18724240
20.

Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.

Powell EL, Leoni LM, Canto MI, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, Maitra A, Montgomery E.

Am J Surg Pathol. 2005 Nov;29(11):1497-504.

PMID:
16224217

Supplemental Content

Support Center